A detailed history of Charles Schwab Investment Management Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 721,050 shares of ETNB stock, worth $6.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
721,050
Previous 667,118 8.08%
Holding current value
$6.01 Million
Previous $5.34 Million 0.15%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$7.36 - $9.66 $396,939 - $520,983
53,932 Added 8.08%
721,050 $5.34 Million
Q2 2024

Aug 12, 2024

BUY
$7.31 - $10.9 $276,939 - $412,946
37,885 Added 6.02%
667,118 $5.34 Million
Q1 2024

May 08, 2024

BUY
$8.13 - $13.77 $1.06 Million - $1.79 Million
129,880 Added 26.01%
629,233 $7.32 Million
Q4 2023

Feb 06, 2024

BUY
$6.66 - $16.03 $68,924 - $165,894
10,349 Added 2.12%
499,353 $5.58 Million
Q3 2023

Nov 08, 2023

BUY
$15.06 - $19.41 $4.85 Million - $6.26 Million
322,339 Added 193.41%
489,004 $7.55 Million
Q2 2023

Aug 09, 2023

BUY
$14.15 - $22.03 $2.06 Million - $3.21 Million
145,639 Added 692.66%
166,665 $3.16 Million
Q1 2023

May 11, 2023

BUY
$10.48 - $16.94 $59,987 - $96,964
5,724 Added 37.41%
21,026 $320,000
Q3 2022

Nov 14, 2022

BUY
$3.02 - $7.0 $46,212 - $107,114
15,302 New
15,302 $89,000
Q2 2022

Aug 15, 2022

SELL
$2.09 - $4.02 $43,185 - $83,065
-20,663 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$3.45 - $14.99 $14,303 - $62,148
-4,146 Reduced 16.71%
20,663 $78,000
Q3 2021

Nov 16, 2021

SELL
$14.91 - $21.31 $567,131 - $810,568
-38,037 Reduced 60.52%
24,809 $487,000
Q2 2021

Aug 16, 2021

BUY
$17.42 - $28.0 $60,377 - $97,048
3,466 Added 5.84%
62,846 $1.18 Million
Q1 2021

May 17, 2021

BUY
$20.22 - $26.73 $93,598 - $123,733
4,629 Added 8.45%
59,380 $1.41 Million
Q4 2020

Feb 16, 2021

BUY
$23.16 - $28.08 $340,521 - $412,860
14,703 Added 36.71%
54,751 $1.34 Million
Q3 2020

Nov 13, 2020

BUY
$24.34 - $38.82 $213,267 - $340,140
8,762 Added 28.01%
40,048 $1.03 Million
Q2 2020

Aug 14, 2020

BUY
$19.93 - $31.2 $49,446 - $77,407
2,481 Added 8.61%
31,286 $624,000
Q1 2020

May 15, 2020

BUY
$16.4 - $41.77 $7,691 - $19,590
469 Added 1.66%
28,805 $728,000
Q4 2019

Feb 07, 2020

BUY
$19.75 - $33.44 $559,636 - $947,555
28,336 New
28,336 $745,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $387M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.